Firms will join complementary capabilities for biotech and pharma industries worldwide.

Albany Molecular Research (AMRI) and Proteros Biostructures announced a strategic alliance that will enable them to jointly offer their respective drug discovery and protein crystallization/x-ray structural analysis services to the life science industry.

Germany-based Proteros specializes in x-ray protein structure analysis. The firm offers a range of products and services. These include: custom gene-to structure projects, screening proteins for primary and secondary screening, biochemical assay development services, and what it claims is the largest collection of gallery structures, established as a catalog of ready-to-use drug targets for analysis as 2-D complex structures with drug candidates.

AMRI offers drug discovery and development, project management, and API/intermediates manufacturing services to clients worldwide. The firm is in addition developing an in-house pipeline of early clinical- and preclinical-stage candidates for a range of therapeutic fields, which it aims to progress in collaboration with strategic partners.

Previous articleTibotec and Gilead Partner to Combine HIV-1 Drugs into Single-Tablet Formulation
Next articleGSK, Lilly Venture Funds Join in Nimbus Discovery’s $24M Series A Financing Round